Barbara Salas, Radiation Oncologist at Dr. Negrín University Hospital of Gran Canaria, shared a post on LinkedIn:
“Exciting research update!
Dr. Zafra will present as oral presentation the results of a prospective multicenter study exploring biomarkers and stereotactic ablative radiotherapy (SABR) in patients with oligoprogressive or oligorecurrent disease.
Our Radiation Oncology Department at Hospital Universitario de Gran Canaria Doctor Negrín is proud to have contributed in this study.
This work evaluates cell-free DNA (cfDNA) and the neutrophil-to-lymphocyte ratio (NLR) as simple, accessible biomarkers to help predict which patients may benefit most from SABR and immune checkpoint inhibitors.
Key findings:
- Promising response rates in both oligoprogressive and oligorecurrent cohorts.
- cfDNA and NLR dynamics correlated with progression-free survival and overall survival.
- Results support their potential as practical biomarkers in clinical decision-making.”
More posts featuring ASTRO25.
